Literature DB >> 26844223

Ibuprofen induced Stevens-Johnson syndrome - toxic epidermal necrolysis in Nepal.

Siddheshwar S Angadi1, Abhishek Karn2.   

Abstract

Despite the fact that any drug can be an impending cause of hypersensitivity reactions, Ibuprofen, an over-the-counter drug used extensively as an analgesic and antipyretic in Asia, is considered to be relatively safe. But herein we report a rare extremely 'rapid onset' occurrence of a severe case of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in a 22-year-old male, induced by 3 doses of 400 mg of Ibuprofen taken at 8-hour interval for eye pain, probably the first case report of rapid onset of TEN by nonsteroidal antiinflammatory drugs in Nepal. SJS and TEN are idiosyncratic, delayed hypersensitivity inflammatory adverse drug reactions that are severe adverse cutaneous drug reactions which predominantly involve the skin and mucous membranes and are linked with high morbidity and mortality. Nevertheless, removal of ibuprofen and its metabolites with plasma exchange and treatment with antibiotics and intravenous corticosteroids along with supportive therapy improved the course of the disorder. This rare case report addresses the fact that severe hypersensitivity reactions can occur with Ibuprofen, which can be potentially dangerous and life threatening. It is thus important for the clinicians to be alert to such severe hypersensitivity reactions even with drugs which are deemed to be probably safe.

Entities:  

Keywords:  Hypersensitivity; Ibuprofen; Immune System Diseases; Stevens-Johnson Syndrome

Year:  2016        PMID: 26844223      PMCID: PMC4731484          DOI: 10.5415/apallergy.2016.6.1.70

Source DB:  PubMed          Journal:  Asia Pac Allergy        ISSN: 2233-8276


INTRODUCTION

Ibuprofen is a common over-the-counter antipyretic-analgesic nonsteroidal antiinflammatory drug whose principal effect is inhibition of cyclooxygenase (prostaglandin-synthase), thus impairing the final transformation of arachidonic acid to prostaglandins, prostacyclin, and thromboxanes. Hypersensitivity-syndrome associated with ibuprofen is a host-dependent idiosyncratic drug-reaction [1]. Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening, bullous cutaneous diseases considered as immune-mediated reactions to drugs characterized by epidermal necrosis, extensive detachment of the epidermis, erosions of mucous membranes and severe constitutional symptoms [23]. This case describes a rare documented rapid-onset hypersensitivity of Ibuprofen causing SJS-TEN in a Nepali male.

CASE REPORT

A 22-year-old Nepali male came to the Emergency Department of a teaching-hospital in central Nepal with chief complaint of sudden appearance of blisters on oral mucosa after taking Ibuprofen 400-mg tablets 8 hourly for 2 days for eye pain. He developed multiple maculae initially over trunk, then chest, face, lower limbs on the third day. He was admitted to the Emergency and upon examination, had extensive erythema (Fig. 1), necrosis, and exfoliating bullous detachment of the epidermis (Fig. 2) and mucous membranes (conjunctival, oral, and genital), with a positive Nikolsky's sign. The body temperature was 38℃, respiratory rate being 24 breaths/min, pulse rate 110 beats/min, blood pressure 130/90 mm Hg, SPO2 98%, and glucose random blood sugar 91 mg/dL.
Fig. 1

Generalised erythematous macules on the trunk with few large confluent flaccid blisters and areas of full detachment.

Fig. 2

Large confluent areas of full detachment of epidermis over heels.

The laboratory analyses are as follows: Na+, 138.8 mmol/L; K+, 4.02 mmol/L; urea, 41.0 mg/dL; creatinine, 1.0 mg/dL; platelet count, 60,000 mm3, white blood cell, 3,600×106/L; hemoglobin, 11.8 g/dL; prothombin (test), 17.5 seconds; prothombin (control), 13.0 seconds; international normalized ratio, 1.37; packed cell volume, 32.05%; bleeding time, 3 minutes; clotting time, 9 minutes; immunodeficiency virus I&II, nonreactive; hepatitis B surface antigen, nonreactive; urine routine examination, pus cells (8–10); C-reactive protein level, 340 mg/L; aspartate aminotransferase, 85 IU/L; alanine aminotransferase, 150 IU/L; total proteins concentration, 50 g/L; and albumin, 20 g/L. Skin biopsy revealed prominent cell death with basal vacuolar changes and lymphocyte infiltrates with haziness in the dermo-epidermal junction which corroborated the clinical diagnosis of SJS-TEN. Ibuprofen was immediately withdrawn and the patient was transferred to the intensive care unit (ICU). On admission to ICU, arterial blood gas analyses are as follows: pH, –7.442; pCO2, 28.5; pO2, 95.5; HCO3, 19.7; blood urea nitrogen, 17.0 mg/dL; blood-sugar random, 162.0; antinuclear antibody enzyme linked immune sorbant assay method, negative. Patient had extensive sloughing off the face (Fig. 3) painful oral erosions with severe crusting of the lips and increased salivation. The plaques with vesicles, sloughed off more than 50% of body surface area which rendered difficulty to access vein on patients limbs. So, central venous pressure line insertion was done and enteral-nutrition was provided via a nasogastric tube. The patient's specific treatment with plasma exchange and fluid resuscitation with crystalloid infusions (1 mL/kg of body weight per hour) fine-tuned on the bases of the arterial blood pressure (>65 mm Hg), central venous pressure (≤10 mm Hg) and diuresis rate [4] was done. The basis for early plasma exchange was to remove/reduce the level of residual ibuprofen and its metabolites, critical cytokines (tumor necrosis factor-alpha [TNF-α], interferon-gamma [IFN-γ]), and drug-induced inflammatory mediators (perforin, granzyme-B released from cytotoxic T-lymphocytes and granulysin secreted by cytotoxic T-lymphocytes and natural killer cells) from the circulation [4]. However, the plasma exchange remain unsupported by controlled studies [5]. Subsequent systemic treatment included intravenous Ceftriaxone 1.0 gm 12 hourly (microbial findings on skin: Staphylococcus aureus and Pseudomonas aeruginosa; the symptoms and signs being warm, tender, erythematous, and edematous plaque over lower extremities with ill-defined borders), intravenous immunoglobulins (IVIG) 1.0-g/kg body weight/day infused over 6 hours for 3 successive days and corticosteroids 0.5-mg/kg body weight. Intravenous tramadol 25 mg was given for analgesia as per the patient's condition. The patient recovered completely after 5 weeks of intensive systemic and topical treatment.
Fig. 3

The patient with nasogastric tube and extensive sloughing off of epidermis of the face.

DISCUSSION

SJS-TEN is a severe life threatening mucocutaneous syndrome caused by hypersensitivity to drugs and is associated with significant morbidity and mortality [6]. It is important to suspect the culprit drug by the temporal relationship (2 days to 8 weeks) [7] but the extremely 'rapid onset' in this case. The exact aetiopathogenesis being imprecise, is thought that some noxious metabolites, inflammatory mediators/modifiers, as well as cytotoxic T-lymphocytes, regulatory T cells and dermal-dendrocytes could provoke apoptosis/necrosis of epithelial cells [8910]. The human leucocyte antigen (HLA) system also plays an important role in the pathogenesis of TEN, since some drugs may bind directly to the HLA-complex and create self-reactivity due to the drug-modified HLA-peptide repertoire [10]. We must take in consideration that regional differences in drug prescription, the genetic background of patients (HLA, metabolizing enzymes) [1112], can have an impact on the incidence so a detailed drug history is extremely significant when go-getting to recognize the offender drug in SJS-TEN. Initial symptoms of SJS-TEN can be unspecific like fever, stinging eyes and discomfort upon swallowing which precede cutaneous manifestations by a few days [13]. Early sites of cutaneous involvement are the presternal region of the trunk, face, palms, and soles. Erythema and erosions of the buccal, genital and/or ocular mucosa occurs in more than 90% of patients, with respiratory and gastrointestinal-tracts affected in few [14]. Prompt removal of causative drug should be the priority and the reported likelihood of a drug causing SJS-TEN can be found in PubMed/MEDLINE or the Litt's-drug-eruption reference manual [15]. Urgent plasma depuration (remain unsupported by controlled studies) [5] with supportive care by management of fluid and electrolyte requirements should be done. Wounds are treated conservatively, without skin debridement as blistered skin acts as a natural biological-dressing which favors re-epithelialization [13]. Topical and systemic medications (antibiotics if infection suspected, IVIG and corticosteroids) should be administered which prevents septicaemia and multisystem organ failure, the major cause of death in SJS-TEN. Recent case reports/series on the use of intravenous methylprednisolone with IVIG, and corticosteroids with infliximab and IVIG have been reported to be effective in arresting progression of TEN and reducing mortality [5]. IVIG, a highly purified IgG possessing anti-Fas activity, anti-infective properties also correcting protein and fluid loss, has for its support multiple, open-label, prospective studies, retrospective case series, and case reports as evidences [16]. Corticosteroids believed to act by suppressing the cytotoxic T-lymphocytes and inhibiting IFN-γ mediated apoptosis, with pleomorphic effects on the immune system including inhibition of chemokines and numerous cytokines like TNF-α [17], are found useful in achieving early control [18].
  17 in total

1.  Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases.

Authors:  Soumya Jagadeesan; K Sobhanakumari; Sadeep Melethil Sadanandan; Sheeba Ravindran; Manjula Velikkakathu Divakaran; Lissy Skaria; George Kurien
Journal:  Indian J Dermatol Venereol Leprol       Date:  2013 Jul-Aug       Impact factor: 2.545

2.  Early treatment with nonsucrose intravenous immunoglobulin in a burn unit reduces toxic epidermal necrolysis mortality.

Authors:  Daniel J Aires; Garth Fraga; Richard Korentager; Coleman P Richie; Smita Aggarwal; Jo Wick; Deede Y Liu
Journal:  J Drugs Dermatol       Date:  2013-06-01       Impact factor: 2.114

3.  Ibuprofen-induced extensive toxic epidermal necrolysis - a multidisciplinary therapeutic approach in a single case.

Authors:  Bela Balint; Nenad Stepic; Milena Todorovic; Lidija Zolotarevski; Gordana Ostojic; Dusan Vucetic; Mirjana Pavlovic; Marijan Novakovic
Journal:  Blood Transfus       Date:  2014-07       Impact factor: 3.443

Review 4.  Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management.

Authors:  Maja Mockenhaupt
Journal:  Semin Cutan Med Surg       Date:  2014-03

5.  Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.

Authors:  Ariane Auquier-Dunant; Maja Mockenhaupt; Luigi Naldi; Osvaldo Correia; Werner Schröder; Jean-Claude Roujeau
Journal:  Arch Dermatol       Date:  2002-08

6.  Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider.

Authors:  David Aguiar; Roberto Pazo; Ignacio Durán; Josefa Terrasa; Antonio Arrivi; Herminio Manzano; Javier Martín; Julio Rifá
Journal:  J Neurooncol       Date:  2004-02       Impact factor: 4.130

7.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.

Authors:  S Bastuji-Garin; B Rzany; R S Stern; N H Shear; L Naldi; J C Roujeau
Journal:  Arch Dermatol       Date:  1993-01

8.  Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis.

Authors:  Sylvia H Kardaun; Marcel F Jonkman
Journal:  Acta Derm Venereol       Date:  2007       Impact factor: 4.437

9.  Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study.

Authors:  F Lebargy; P Wolkenstein; M Gisselbrecht; F Lange; J Fleury-Feith; C Delclaux; E Roupie; J Revuz; J C Roujeau
Journal:  Intensive Care Med       Date:  1997-12       Impact factor: 17.440

Review 10.  Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective.

Authors:  Bernard Yu-Hor Thong
Journal:  Asia Pac Allergy       Date:  2013-10-31
View more
  6 in total

1.  Stevens-Johnson Syndrome Following Non-steroidal Anti-inflammatory Drugs: A Real-World Analysis of Post-marketing Surveillance Data.

Authors:  Qi-Hui Shao; Xue-Dong Yin; Na Zeng; Zhi-Xuan Zhou; Xin-Yu Mao; Yan Zhu; Bin Zhao; Zhi-Ling Li
Journal:  Front Pediatr       Date:  2022-05-06       Impact factor: 3.569

Review 2.  Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities.

Authors:  Adegbenro Omotuyi John Fakoya; Princess Omenyi; Precious Anthony; Favour Anthony; Precious Etti; David Adeiza Otohinoyi; Esther Olunu
Journal:  Open Access Maced J Med Sci       Date:  2018-03-28

3.  Bibliometric analysis of adverse drug reactions and pharmacovigilance research activities in Nepal.

Authors:  Sunil Shrestha; Krisha Danekhu; Bhuvan Kc; Subish Palaian; Mohamed Izham Mohamed Ibrahim
Journal:  Ther Adv Drug Saf       Date:  2020-06-12

4.  Diagnosis and treatment of flurbiprofen-induced Stevens-Johnson syndrome: A rare case report.

Authors:  Asad Ali Khan; Farhana Rashid; Farhat Ullah Khan; Tahmina Tahmina; Said Amin; Ayush Anand
Journal:  Clin Case Rep       Date:  2022-09-23

5.  Survey of Nonprescription Medication and Antibiotic Use in Patients with Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Overlap Syndrome.

Authors:  Katherine J Sullivan; Meghan N Jeffres; Robert P Dellavalle; Robert Valuck; Heather D Anderson
Journal:  Antibiotics (Basel)       Date:  2018-02-01

Review 6.  NSAID-induced reactions: classification, prevalence, impact, and management strategies.

Authors:  Natalia Blanca-Lopez; Victor Soriano; Elena Garcia-Martin; Gabriela Canto; Miguel Blanca
Journal:  J Asthma Allergy       Date:  2019-08-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.